Evidence map›Paper›PMID 31734851›Full record

ArticlePituitary2020

Association of NM23 polymorphisms and clinicopathological features and recurrence of invasive pituitary adenomas.

Hua Wang, Wenyuan Sang

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hua Wang1st Ward of Department of Neurosurgery, Chifeng Municipal Hospital, No. 1, Zhaowuda Road, Chifeng, 024000, Inner Mongolia Autonomous Region, People's Republic of China.
Wenyuan Sang1st Ward of Department of Neurosurgery, Chifeng Municipal Hospital, No. 1, Zhaowuda Road, Chifeng, 024000, Inner Mongolia Autonomous Region, People's Republic of China. cfsyywh@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPituitary adenomas (PAs) are intracranial tumors, deriving from anterior pituitary cells. Previously, expression of non-metastasis-23 (NM23) gene has been shown to correlate with the progression of PAs. In this study, we aim to determine whether there is association between specific NM23 polymorphisms and invasive pituitary adenoma (IPA).

methodsGenotypes of rs2302254 and rs16949649 of NM23 were identified in the peripheral venous blood of patients by PCR-RLFP. Next, the correlation between specific genotypes of rs2302254 and rs16949649 and risk of IPA was investigated. Finally, the correlations between NM23 polymorphisms and tumor size, Ki67 LI and recurrence of IPA were analyzed with 3 to 24 months follow-up for the enrolled patients.

resultsWe observed that the TT genotype at rs16949649 correlated closely with a high risk of IPA, while CC and CT genotypes reduced the risk of IPA. CC genotype at rs2302254 increased the risk of IPA, while CT and TT genotypes reduced the risk of IPA. T

conclusionTaken together, the present study provides evidence that NM23 polymorphisms are closely associated with the incidence and recurrence of IPA. Specifically, TT genotype at rs16949649 and CC genotype at rs2302254 are risk factors of IPA. NM23 polymorphisms could therefore be used as a reference for clinical diagnosis and prognosis of IPA.

Indexed as

AdultAgedAged, 80 and overFemaleGenetic Predisposition to DiseaseGenotypeHumansImmunohistochemistryMaleMiddle AgedNeoplasm Recurrence, LocalNM23 Nucleoside Diphosphate KinasesPituitary NeoplasmsPolymorphism, Single NucleotidePrognosisYoung AdultNM23 Nucleoside Diphosphate KinasesNME1 protein, humanHaplotype analysisInvasive pituitary adenomaNM23Pathological characteristicsPolymorphismsRecurrence

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.